Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Abstracts from the NIH Office of Research on Women's HealthNinth Annual Interdisciplinary Women's Health Research SymposiumNovember 15, 2012 : Ninth Annual NIH Interdisciplinary Women's Health Research Symposium November 15, 2012

ABSTRACT:

SUBMITTER:

PROVIDER: S-EPMC3466925 | biostudies-literature | 2012 Oct

REPOSITORIES: biostudies-literature

ACCESS DATA

Json Xml

Similar Datasets

Abstracts from the NIH Office of Research on Women's Health Eighth Annual Interdisciplinary Women's Health Research Symposium November 17, 2011 : Eighth Annual NIH Interdisciplinary Women's Health Research Symposium November 17, 2011

Project description: Not available

| S-EPMC3197080 | biostudies-literature

Ninth Annual Diabetes Technology Meeting, November 5-7, 2009, San Francisco

Project description: Not available

| S-EPMC2864185 | biostudies-literature

Abstracts of the Ninth International Symposium on Functional Neuroreceptor Mapping of the Living Brain. August 9-11, 2012.

Project description: Not available

| S-EPMC3421080 | biostudies-literature

Proceedings of the 3rd Annual Albert Institute for Bladder Cancer Research Symposium.

Project description:The Third Annual Albert Institute Bladder Symposium was held on September 8-10th, 2016, in Denver Colorado. Participants discussed several critical topics in the field of bladder cancer: 1) Best practices for tissue analysis and use to optimize correlative studies, 2) Modeling bladder cancer to facilitate understanding and innovation, 3) Targeted therapies for bladder cancer, 4) Tumor phylogeny in bladder cancer, 5) New Innovations in bladder cancer diagnostics. Our understanding of and approach to treating urothelial carcinoma is undergoing rapid advancement. Preclinical models of bladder cancer have been leveraged to increase our basic and mechanistic understanding of the disease. With the approval of immune checkpoint inhibitors for the treatment of advanced urothelial carcinoma, the treatment approach for these patients has quickly changed. In this light, molecularly-defined subtypes of bladder cancer and appropriate pre-clinical models are now essential to the further advancement and appropriate application of these therapeutic improvements. The optimal collection and processing of clinical urothelial carcinoma tissues samples will also be critical in the development of predictive biomarkers for therapeutic selection. Technological advances in other areas including optimal imaging technologies and micro/nanotechnologies are being applied to bladder cancer, especially in the localized setting, and hold the potential for translational impact in the treatment of bladder cancer patients. Taken together, advances in several basic science and clinical areas are now converging in bladder cancer. These developments hold the promise of shaping and improving the clinical care of those with the disease.

| S-EPMC5545918 | biostudies-literature

NIH Primary and Secondary Prevention Research in Humans During 2012-2017.

Project description:IntroductionThis paper provides the first detailed analysis of the NIH prevention research portfolio for primary and secondary prevention research in humans and related methods research.MethodsThe Office of Disease Prevention developed a taxonomy of 128 topics and applied it to 11,082 projects representing 91.7% of all new projects and 84.1% of all dollars used for new projects awarded using grant and cooperative agreement activity codes that supported research in fiscal years 2012-2017. Projects were coded in 2016-2018 and analyzed in 2018.ResultsOnly 16.7% of projects and 22.6% of dollars were used for primary and secondary prevention research in humans or related methods research. Most of the leading risk factors for death and disability in the U.S. were selected as an outcome in <5% of the projects. Many more projects included an observational study, or an analysis of existing data, than a randomized intervention. These patterns were consistent over time.ConclusionsThe appropriate level of support for primary and secondary prevention research in humans from NIH will differ by field and stage of research. The estimates reported here may be overestimates, as credit was given for a project even if only a portion of that project addressed prevention research. Given that 74% of the variability in county-level life expectancy across the U.S. is explained by established risk factors, it seems appropriate to devote additional resources to developing and testing interventions to address those risk factors.

| S-EPMC6251492 | biostudies-literature

2nd PEGS Annual Symposium on Antibodies for Cancer Therapy: April 30-May 1, 2012, Boston, USA.

Project description:The 2nd Annual Antibodies for Cancer Therapy symposium, organized again by Cambridge Healthtech Institute as part of the Protein Engineering Summit, was held in Boston, USA from April 30th to May 1st, 2012. Since the approval of the first cancer antibody therapeutic, rituximab, fifteen years ago, eleven have been approved for cancer therapy, although one, gemtuzumab ozogamicin, was withdrawn from the market. The first day of the symposium started with a historical review of early work for lymphomas and leukemias and the evolution from murine to human antibodies. The symposium discussed the current status and future perspectives of therapeutic antibodies in the biology of immunoglobulin, emerging research on biosimilars and biobetters, and engineering bispecific antibodies and antibody-drug conjugates. The tumor penetration session was focused on the understanding of antibody therapy using ex vivo tumor spheroids and the development of novel agents targeting epithelial junctions in solid tumors. The second day of the symposium discussed the development of new generation recombinant immunotoxins with low immunogenicity, construction of chimeric antigen receptors, and the proof-of-concept of 'photoimmunotherapy'. The preclinical and clinical session presented antibodies targeting Notch signaling and chemokine receptors. Finally, the symposium discussed emerging technologies and platforms for therapeutic antibody discovery.

| S-EPMC3499296 | biostudies-literature

Abstracts of the Eighth Annual Diabetes Technology Meeting, November 13-15, 2008, Bethesda, Maryland, USA.

Project description: Not available

| S-EPMC2771524 | biostudies-literature

Diet and Physical Activity Prevention Research Supported by the U.S. NIH From 2012-2017.

Project description:IntroductionPoor diet and inadequate physical activity are common contributors to preventable death in the U.S. This paper provides a summary of the NIH-sponsored research on disease prevention that underlies public health and clinical recommendations to improve diet and physical activity.MethodsA representative sample (n=11,082) of research grants and cooperative agreements (research projects) representing the NIH prevention research portfolio between 2012 and 2017 were hand coded by trained analysts in 2017-2018. This manuscript describes the rationale(s), exposure(s), outcome(s), population(s), and study design(s) in prevention research focused on diet and physical activity and compares this research to identified research gaps in the field.ResultsA relatively stable 7.8% (95% CI=7.0%, 8.8%) and 5.0% (95% CI=4.4%, 5.7%) of the NIH prevention research projects were focused on diet and physical activity, respectively, during 2012-2017. These projects often explored diet and physical activity together in the context of obesity, included observational studies, and focused on a general adult population. Few of these projects focused on development of improved assessment methods. Approximately 50% of these studies were related to research gaps identified by the 2015 Dietary or 2018 Physical Activity Guidelines Advisory Committee Scientific Reports.ConclusionsOpportunities exist for more engagement by NIH and scientific investigators in diet- and physical activity-focused prevention research, particularly around assessment and known research gaps.

| S-EPMC6894494 | biostudies-literature

INTERNATIONAL SYMPOSIUM ON RADIOPHARMACEUTICAL THERAPY HELSINKI, 18-20 NOVEMBER 2018

Project description: Not available

| S-EPMC6476247 | biostudies-literature

3rd International Cancer Research Symposium 2012: defining & translating science for disease prevention and therapy, Kolkata, West Bengal, India, December 18-21, 2012.

Project description: Not available

| S-EPMC3590366 | biostudies-literature